President Donald Trump ‘s administration is preparing a new probe into drug pricing practices among US trading partners, a move that would lay the ground for fresh tariffs , the Financial Times reported on Wednesday, citing sources familiar with the matter.

US to launch Section 301 investigation into drug pricing by trading partners:

Reuters could not immediately verify the report.The imminent investigation would consider whether US trading partners are underpaying for drugs, the report said, adding that the investigation would come under Section 301 of the Trade Act of 1974.

The White House did not immediately respond to a Reuters’ request for comment. US patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations

See Full Page